{{ currentBoardShortName }}
  • Markets
  • Indices
  • Currencies
  • Energy
  • Metals
Markets
As of: {{timeStamp.date}}
{{timeStamp.time}}

Markets

{{ currentBoardShortName }}
  • Markets
  • Indices
  • Currencies
  • Energy
  • Metals
{{data.symbol | reutersRICLabelFormat:group.RICS}}
 
{{data.netChng | number: 4 }}
{{data.netChng | number: 2 }}
{{data | displayCurrencySymbol}} {{data.price | number: 4 }}
{{data.price | number: 2 }}
{{data.symbol | reutersRICLabelFormat:group.RICS}}
 
{{data.netChng | number: 4 }}
{{data.netChng | number: 2 }}
{{data | displayCurrencySymbol}} {{data.price | number: 4 }}
{{data.price | number: 2 }}

Commodities Videos

VIDEO SIGN OUT

{{ currentStream.Name }}

{{ currentStream.Desc }}

Related Video

Continuous Play:
ON OFF

The information you requested is not available at this time, please check back again soon.

Feb 28, 2018

Pot producer Aurora gets final regulatory nod for CanniMed purchase

Aurora Cannabis plants

Security Not Found

The stock symbol {{StockChart.Ric}} does not exist

See Full Stock Page »

Canada's No.2 marijuana producer Aurora Cannabis Inc (ACB.TO) on Wednesday received final regulatory approval for the purchase of smaller rival CanniMed Therapeutics Inc (CMED.TO), which would make it the world's most valuable weed producer.

The approval of the $1.1 billion deal from the Competition Bureau follows months of tensions between the companies and comes at a time when companies are jostling to gain from the country's legalization of recreational use of pot.

Aurora had initially made a hostile bid capped at $24 per share for CanniMed in November and increased it to $43 in the new offer.

Cannimed, which was already engaged in a friendly deal to buy Newstrike Resources (HIP.V), canceled it in January in favor of the increased Aurora offer.